FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.

@article{Child2000FLUDAPSC,
  title={FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.},
  author={J. Anthony Child and Stephen A N Johnson and Simon Rule and Graeme Murray Smith and Gareth J Morgan and Peter W M Johnson and Archie G Prentice and Sall Tollerfield and E Wareham},
  journal={Leukemia & lymphoma},
  year={2000},
  volume={37 3-4},
  pages={309-17}
}
The aim of this study was to investigate the combination of fludarabine phosphate, dexamethasone, cytosine arabinoside and cis-platinum (FLUDAP) in the treatment of patients with relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL). This regimen comprises: dexamethasone 100 mg/d continuous infusion (cont. inf.) d1-3; cytosine arabinoside (ara-C) 1 g/m2/d cont. inf. d 2,3; fludarabine phosphate 30 mg/m2 short inf. 4hr prior to each 24hr ara-C inf.; cis-platinum 50 mg/m2 4hr inf. at the… CONTINUE READING